Related Experiment Video
Updated: Jan 23, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
Published on: May 17, 2019
Immunogenicity and skin clearance recapture in clinical studies of brodalumab
Jerry Bagel1, Mark Lebwohl2, Robert J Israel3
1Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey.
Background:
Antidrug antibodies (ADAs) may change pharmacokinetic or pharmacodynamic profiles of biologic therapies, potentially decreasing efficacy.
Objective:
To evaluate the potential effects of brodalumab immunogenicity on safety, efficacy, and retreatment.
Methods:
Data from 1 phase 2 and 3 phase 3 studies of brodalumab in psoriasis were analyzed.
Results:
Overall, 2.7% of patients had positive test results for binding ADAs after receiving brodalumab; ADAs were transient in 1.4% of patients, and there were no neutralizing ADAs. Among ADA-positive patients, 60.0% (3/5) achieved a static physician's global assessment score of 0 or 1 at week 12 in the group receiving the brodalumab 210 mg every 2 weeks, compared with 79.1% (1131/1429) of ADA-negative patients. All patients (100%) who experienced return of disease and were retreated with brodalumab 210 mg every 2 weeks (none were ADA positive) achieved at least a 75% improvement in Psoriasis Area And Severity Index, ≥90% of whom regained response by week 8 of retreatment. Hypersensitivity reactions were less frequent with brodalumab than with placebo. Injection site reactions occurred in 1.8% of patients treated with brodalumab versus 2% of patients treated with ustekinumab.
Limitations:
Retreatment could be assessed in only 1 phase 3 brodalumab study.
Conclusion:
Brodalumab compares favorably with other biologics in terms of immunogenicity and high rates of efficacy recapture upon retreatment.
Related Concept Videos
Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Most drugs undergo restrictive clearance, which is proportional to the...
Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Drug Clearance: Overview
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
Hypertension III: Clinical Manifestations and Diagnostic Studies

